Recent

% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

  • icprecipice icprecipice Dec 6, 2012 2:00 PM Flag

    Does Stelios Make Another Move?

    Stelios Papadopoulos was probably locked out from purchasing shares during the lead-up to Cometriq's approval. In August, 2010, he bought a load of shares on the open market, when future prospects looked pretty dim for EXEL. As a self-professed long-term investor (5-10 year time frame), you have to think that he might have an interest in buying additional shares in this price range. It'll be interesting to see if he has the confidence to double-down on his conviction that EXEL is still an excellent investment for the long term.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • It's also noteworthy that ANDS's Hep C drug had just announced P2 results days before Roche agreed to buy them out at a 265% premium. If you check ANDS's partners they are eerily similar to EXEL's partners. Roche already has a STRONG working relationship with EXEL and they could buy out EXEL for what they have in petty cash ($3B) and not even blink.

      Sentiment: Strong Buy

 
EXEL
11.57-0.04(-0.34%)12:47 PMEDT